drugset

drugset / Trial / NCT00719316

Aliskiren and Muscle Sympathetic Nerve Activity

NCT00719316 ↗

Phase 4 Unknown 30 enrolled UMC Utrecht

RandomizedCrossoverOpen-labelTreatment

Summary

The central hypothesis of this project is that Aliskiren causes a substantial decrease in MSNA in hypertensive patients with CKD.

Timeline

Start: 2008-07
Primary completion: 2009-07
Completion: 2010-01

Publications

Siddiqi L, Oey PL, Blankestijn PJ. Aliskiren reduces sympathetic nerve activity and blood pressure in chronic kidney disease patients. Nephrol Dial Transplant. 2011 Sep;26(9):2930-4. doi: 10.1093/ndt/gfq857. Epub 2011 Apr 5.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Aliskiren	Small molecule	300 mg	—

Indications